Candel Therapeutics (CADL) Receivables - Net (2020 - 2021)
Candel Therapeutics recorded quarterly Receivables - Net of $1.1 million in Q4 2021, up 463.35% quarter-over-quarter from $191000.0 in Q1 2021, and up 72.44% year-over-year from $624000.0 in Q4 2020.
Candel Therapeutics' Receivables - Net history runs 2 years deep, the most recent figure standing at $1.1 million for Q4 2021.
- In Q4 2021, Receivables - Net rose 72.44% year-over-year to $1.1 million; the TTM figure through Dec 2021 stood at $1.1 million (up 72.44% YoY), while the FY2021 annual figure was $1.1 million, up 72.44% from the prior year.
- Receivables - Net came in at $1.1 million for Q4 2021 at Candel Therapeutics, up from $191000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $1.1 million in Q4 2021 to a low of $191000.0 in Q1 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 1.08 Mn |
| Dec 31, 2021 | 1.08 Mn |
| Mar 31, 2021 | 191,000.00 |
| Mar 31, 2021 | 191,000.00 |
| Dec 31, 2020 | 624,000.00 |
| Dec 31, 2020 | 624,000.00 |